Collaboration combines MPC’s specialized media supplements with GenSensor’s bioprocess analytics to enhance yield and product quality across AAV, protein and exosome production platforms

Nantes – Geneva, February 2026 – MPC Therapeutics, a leading provider of specialized cell culture media supplements, and GenSensor, an innovator in bioprocess development and optimization, today announced a strategic partnership to expand media optimization capabilities across gene therapy and biologics production.

The collaboration will extend the application of MPC’s proven media supplements into high-value segments, including adeno-associated virus (AAV) production in HEK cell lines, monoclonal antibody (mAb) and recombinant protein manufacturing in CHO cell lines. GenSensor will contribute its expertise in bioprocess development support and proprietary biomarkers related to cellular energy metabolism to demonstrate and optimize media supplementation strategies.

Improving Yield and Product Quality

The partnership addresses a key challenge facing biomanufacturers: maximizing both productivity and product quality in increasingly complex production systems. By integrating MPC’s targeted media supplementation strategies with GenSensor bio-pathways monitoring capabilities, the companies aim to demonstrate that precision media supplementation can simultaneously improve yields and Critical Quality Attributes (CQAs).

« This partnership allows us to bring our media optimization expertise to new markets where manufacturers need better tools for improving both output and quality, » said Raphaël Martinou at MPC Therapeutics. « GenSensor AI-based biomarker analytic platform provides the data-driven insights needed to guide effective media supplementation. »

Combining Complementary Expertise

MPC Therapeutics brings proven experience in developing specialized supplements that reprogram cell behaviour through metabolic modulation. GenSensor contributes advanced bioprocess analytics that track cellular production pathways, providing insight into how cells respond to media modifications and confirm cell fit.

This combination enables a data-driven approach to media development, where metabolic modulation strategies are guided by direct measurement of cellular state.

« Energy metabolism and produced chaperones drives both cell growth and product synthesis, » said Charles Hébert at GenSensor. « Our biomarkers show exactly how cells are utilizing nutrients, generating energy and associated proteins that enhance the quality of the product. Combined with MPC’s targeted supplements, we can optimize this process for better efficiency and product quality. »

Market Applications

The initial focus areas represent growing and technically demanding segments in biomanufacturing:

AAV Production (HEK Cell Lines): Gene therapies require high-titre AAV production with optimal capsid quality. The partnership will develop media supplementation protocols that enhance both productivity and the percentage of full capsids.

mAb and Recombinant Protein Production (CHO Cell Lines): Biologics manufacturers face increasing pressure to improve titres while maintaining glycosylation profiles and other quality attributes. The collaboration will demonstrate how targeted media complements can achieve both objectives.

Exosome Production: As exosome-based therapeutics advance toward commercialization, manufacturers need scalable processes that deliver consistent yields and cargo loading efficiency. The partnership will apply metabolic optimization strategies to improve exosome quantity, quality, and therapeutic payload delivery.

Next Steps

The companies plan to conduct joint proof-of-concept studies over the coming months, with results to be presented at industry conferences. Commercial products and services resulting from the collaboration are expected to launch in 9 to 12 months.

« This partnership is taking an innovative yet practical approach to bioprocess optimization » added Raphel Martinou. « By giving manufacturers better visibility into cellular metabolism and the right tools to adjust it, we can help them improve both the quantity and quality of what they produce. »

About MPC Therapeutics

MPC Therapeutics is a Swiss biotech company pioneering mitochondrial-targeted solutions for biomanufacturing, cell therapy and therapeutics applications. Based in Geneva, Switzerland, MPC develops proprietary small molecule supplements that modulate cellular energy metabolism through targeted inhibition of the mitochondrial pyruvate carrier, as well as other metabolic targets. The company’s flagship product, MitoStem™, is a first-in-class ex vivo reagent that enhances cell therapy performance by inducing metabolic reprogramming. Founded as a spin-off from the University of Geneva and the first Swiss company to join Johnson & Johnson’s JLABS incubator, MPC Therapeutics combines world-class expertise in mitochondrial biology with practical biomanufacturing solutions.

About GenSensor

GenSensor is a French biotech company transforming biological process analytical technologies through AI-powered biomarker detection and automated sampling systems. Founded in 2021 and based in Nantes, France, GenSensor integrates advanced robotic devices with mRNA-based biomarker analytics to monitor, characterize, and optimize bioproduction of ATMPs, vaccines, and biologics. The company’s GenSampler automated sampling device combined with its proprietary gene expression analysis services provides real-time insights into cell signalling pathways and metabolic states, enabling upstream process optimization from R&D through commercial manufacturing. GenSensor’s mission is to promote access to innovative biologic medicines by optimizing bioproduction for the benefit of patients.

Contact

Raphael Martinou, MPC Therapeutics, raphael.martinou@mpc-therapeutics.com

Charles Hébert, GenSensor, charles.hebert@gensensor.com